YoY Growth of Top 10 BioPharma companies by Q2 2024 Sales

The top 10 BioPharma companies by sales in Q2 saw an 8% YoY growth overall, with Eli Lilly leading the pack in YoY growth rate. Several non-Top 10 companies also exhibited notable growth. Here is a look at some key growth drivers:

September 11, 2024

Pfizer Delivers Robust Q2 2024 Performance, Raises Full-Year Guidance

Pfizer raised its full-year sales guidance by $1 billion after announcing Q2 2024 results, with $13.3 billion in revenues and 3% YoY operational growth despite anticipated COVID-related sales declines. Here are some of the notable growth drivers.

September 11, 2024

Roche's Pharmaceutical Division Performance in Q2 YoY

Roche's Pharmaceutical Division witnessed strong growth in Q2 2024, driven by the performance of its blockbuster therapies. This report provides an in-depth analysis of the key drivers behind this success and the company's strategic initiatives to maintain its leadership position in various therapeutic areas.

September 11, 2024

Notable Biopharma Fundraises in August: Powering Promising Treatments

In August, ~20 notable Biotech fundraises soaked up a combined $1.2B, helping power work on several promising treatments across various indications and modalities. Here are some highlights:

September 09, 2024

Epidemiologies of Oncology: Insights from AstraZeneca and Novartis

Oncology is uniquely complex because of the large number of variations, each of which often requires a different type of medicine. Here’s a look at the epidemiology of breast and lung cancer, and some leading treatments:

September 09, 2024

Massachusetts Biopharma Industry Snapshot 2024

Last week, MassBio published their annual biopharma Industry Snapshot covering key topics including funding and employment. Despite positive momentum in capital markets, MA-based biotechs saw a dip in VC funding to the lowest point since 2019. Here are other highlights:

September 05, 2024

New EMA Medicine Approvals Through August 2024

In the first eight months of 2024, the EMA approved 45 new drugs, keeping pace with the 77 it approved in 2023. Here’s a dive into the latest EMA approvals initiative and the details of new approvals:

September 04, 2024

Revolutionizing Cancer Treatment: The Emergence of mRNA Vaccines

BioNTech recently launched Phase 1 trials for its mRNA lung cancer vaccine, one of ~70 clinical trials exploring using mRNA vaccines against cancer. Here’s a closer look at mRNA vaccines as a potential cancer therapy:

September 04, 2024

Crowning Achievements: Recent Royalty Deals in BioPharma

Are royalty deals the new savior of BioPharma cash burn? Challenging capital markets have made these deals more attractive to all players:

September 03, 2024

BioPharma's Direct-to-Consumer Evolution

Last week, Pfizer launched a new DTC website called Pfizer for All, highlighting increasing efforts by BioPharma companies to engage directly with consumers, who neither write checks or make prescribing decisions:

September 03, 2024